

Antonio Bianchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4739680/publications.pdf>

Version: 2024-02-01

113
papers

4,195
citations

101384

36
h-index

123241

61
g-index

116
all docs

116
docs citations

116
times ranked

3719
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results. <i>Endocrine</i> , 2022, 76, 224-227.	1.1	2
2	The changing clinical spectrum of endocrine adverse events in cancer immunotherapy. <i>Trends in Endocrinology and Metabolism</i> , 2022, 33, 87-104.	3.1	11
3	Second line treatment of acromegaly: Pasireotide or Pegvisomant?. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101684.	2.2	11
4	Risk factors for pancreas and lung neuroendocrine neoplasms: a case-control study. <i>Endocrine</i> , 2021, 71, 233-241.	1.1	9
5	Empty sella syndrome: Multiple endocrine disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 181, 29-40.	1.0	12
6	Hypothalamitis and pituitary atrophy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 181, 149-159.	1.0	2
7	Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study. <i>Endocrine</i> , 2021, 73, 308-315.	1.1	6
8	Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. <i>European Journal of Endocrinology</i> , 2021, 184, 217-229.	1.9	24
9	Diabetic neuropathy: a risk factor for severe COVID-19?. <i>Acta Diabetologica</i> , 2021, 58, 669-670.	1.2	6
10	Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. <i>Endocrine</i> , 2021, 73, 658-666.	1.1	11
11	Gene Expression Profiling of Pancreas Neuroendocrine Tumors with Different Ki67-Based Grades. <i>Cancers</i> , 2021, 13, 2054.	1.7	10
12	Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. <i>Cancers</i> , 2021, 13, 3252.	1.7	12
13	Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study. <i>Frontiers in Endocrinology</i> , 2021, 12, 684055.	1.5	6
14	Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study. <i>BMC Geriatrics</i> , 2021, 21, 598.	1.1	6
15	Spontaneous Thyroid Nodule Hemorrhage in the Emergency Department. <i>Endocrine Practice</i> , 2020, 26, 192-196.	1.1	14
16	Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e100-e107.	1.8	33
17	Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in) Tj ETQq1 1 0.784314 rgBT /Overl	1.8	18
18	Acromegaly in the elderly patients. <i>Endocrine</i> , 2020, 68, 16-31.	1.1	24

#	ARTICLE	IF	CITATIONS
19	Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. <i>Endocrine</i> , 2020, 67, 651-658.	1.1	19
20	Euthyroid sick syndrome in hip fractures: Valuation of vitamin D and parathyroid hormone axis. <i>Injury</i> , 2020, 51, S13-S16.	0.7	12
21	Proteomics of Pancreatic Neuroendocrine Tumors: A Systematic Review. <i>Protein and Peptide Letters</i> , 2020, 27, 1276-1287.	0.4	2
22	The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility. <i>Protein and Peptide Letters</i> , 2020, 27, 1260-1267.	0.4	4
23	The Changing Clinical Spectrum of Hypophysitis. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 590-602.	3.1	35
24	First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 365.	1.5	1
25	Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5478-5482.	1.8	23
26	Protein Expression of PTTG-1, OCT-4, and KLF-4 in Seminoma: A Pilot Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 619.	1.5	7
27	Effects of Thyroid Hormone Treatment on Diaphragmatic Efficiency in Mechanically Ventilated Subjects With Nonthyroidal Illness Syndrome. <i>Respiratory Care</i> , 2019, 64, 1199-1207.	0.8	12
28	Acromegaly can be cured by first-line pasireotide treatment?. <i>Endocrine</i> , 2019, 64, 196-199.	1.1	7
29	Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 429-443.	1.2	13
30	Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. <i>Journal of Neuroendocrinology</i> , 2019, 31, e12692.	1.2	4
31	Somatotropic Axis in Human Aging. , 2019, , 700-707.		1
32	Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. <i>Pituitary</i> , 2018, 21, 302-308.	1.6	30
33	Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients. <i>Clinical Endocrinology</i> , 2018, 88, 692-699.	1.2	17
34	Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study. <i>Endocrine</i> , 2018, 60, 362-367.	1.1	16
35	How to improve effectiveness of pegvisomant treatment in acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 575-581.	1.8	18
36	Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. <i>Endocrine</i> , 2018, 59, 449-453.	1.1	29

#	ARTICLE	IF	CITATIONS
37	Use of ¹¹¹ In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma. <i>Endocrine</i> , 2018, 60, 532-534.	1.1	8
38	Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3877-3889.	1.8	30
39	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018, 107, 375-386.	1.2	78
40	Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis. <i>Pituitary</i> , 2018, 21, 414-424.	1.6	20
41	An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Prospective Single-Center Experience. <i>Neuroendocrinology</i> , 2017, 104, 280-290.	1.2	36
42	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017, 24, 495-504.	1.6	61
43	DIAGNOSIS OF ENDOCRINE DISEASE: Primary empty sella: a comprehensive review. <i>European Journal of Endocrinology</i> , 2017, 177, R275-R285.	1.9	104
44	Understanding the effect of acromegaly on the human skeleton. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 263-270.	1.2	10
45	Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. <i>Clinical Endocrinology</i> , 2016, 85, 717-724.	1.2	15
46	Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia. <i>Endocrine</i> , 2016, 53, 636-642.	1.1	24
47	Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. <i>European Journal of Endocrinology</i> , 2016, 174, 241-250.	1.9	122
48	Increased FGF23 serum level is associated with unstable carotid plaque in type 2 diabetic subjects with internal carotid stenosis. <i>Cardiovascular Diabetology</i> , 2015, 14, 139.	2.7	21
49	Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis. <i>Neuroendocrinology</i> , 2015, 101, 143-150.	1.2	69
50	Systemic mastocytosis mimicking carcinoid syndrome. <i>Endocrine</i> , 2015, 48, 718-719.	1.1	2
51	Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. <i>Pituitary</i> , 2014, 17, 267-76.	1.6	44
52	GH receptor isoforms and skeletal fragility in acromegaly. <i>European Journal of Endocrinology</i> , 2014, 171, 237-245.	1.9	25
53	Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism. <i>European Journal of Endocrinology</i> , 2014, 170, 893-899.	1.9	34
54	Hypothalamitis: a diagnostic and therapeutic challenge. <i>Pituitary</i> , 2014, 17, 197-202.	1.6	20

#	ARTICLE	IF	CITATIONS
55	Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 40.	3.5	41
56	A Rare Case of Malignant Granular Cell Tumor of the Colon Incidentally Detected by 18â€‰F-FDG Positron Emission Tomography/Computed Tomography. <i>Nuclear Medicine and Molecular Imaging</i> , 2013, 47, 148-150.	0.6	6
57	Double pituitary adenomas. <i>Endocrine</i> , 2013, 43, 452-457.	1.1	18
58	Vertebral Fractures in Patients With Acromegaly: A 3-Year Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3402-3410.	1.8	131
59	Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGFâ€‰I levels. <i>Clinical Endocrinology</i> , 2012, 77, 531-536.	1.2	49
60	Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a caseâ€‰control study. <i>Pituitary</i> , 2012, 15, 571-578.	1.6	42
61	Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. <i>Gastrointestinal Endoscopy</i> , 2012, 76, 570-577.	0.5	158
62	Predictors of morbidity and mortality in acromegaly: an Italian survey. <i>European Journal of Endocrinology</i> , 2012, 167, 189-198.	1.9	189
63	Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. <i>Journal of Endocrinological Investigation</i> , 2012, 35, 817-23.	1.8	64
64	The exon 3-deleted growth hormone receptor: Molecular and functional characterization and impact on GH/IGF-I axis in physiological and pathological conditions. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 861-868.	1.8	12
65	ACTH-dependent Cushing syndrome: The potential benefits of simultaneous bilateral posterior retroperitoneoscopic adrenalectomy. <i>Surgery</i> , 2011, 149, 299-300.	1.0	14
66	Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. <i>Pituitary</i> , 2011, 14, 351-357.	1.6	40
67	High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas. <i>Pituitary</i> , 2011, 14, 299-306.	1.6	70
68	Vertebral fractures in males with prolactinoma. <i>Endocrine</i> , 2011, 39, 288-293.	1.1	85
69	Influence of diabetes mellitus on vertebral fractures in men with acromegaly. <i>Endocrine</i> , 2011, 40, 102-108.	1.1	53
70	The treatment of neuroendocrine tumors with long-acting somatostatin analogs: a single center experience with lanreotide autogel. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 692-7.	1.8	11
71	Endoscopic Ultrasound-Guided Fine Needle Tissue Acquisition (EUS-FNTA) Using a 19-G Needle for Histological Grading of Pancreatic Endocrine Tumors (PETs): A Prospective Study. , 2011, , P3-255-P3-255.		0
72	Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. <i>European Journal of Endocrinology</i> , 2010, 163, 15-20.	1.9	58

#	ARTICLE	IF	CITATIONS
73	Two Diagnostic Pitfalls Mimicking a Prolactin-Secreting Microadenoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 5171-5171.	1.8	3
74	Nonthyroidal Illness Syndrome and Prolonged Mechanical Ventilation in Patients Admitted to the ICU. <i>Chest</i> , 2009, 135, 1448-1454.	0.4	76
75	Influence of Growth Hormone Receptor d3 and Full-Length Isoforms on Biochemical Treatment Outcomes in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2015-2022.	1.8	69
76	Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly. <i>Pituitary</i> , 2009, 12, 196-199.	1.6	46
77	The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature. <i>Fertility and Sterility</i> , 2009, 91, 930.e7-930.e11.	0.5	45
78	The long-term cardiovascular outcome of different GH-lowering treatments in acromegaly. <i>Pituitary</i> , 2008, 11, 13-20.	1.6	46
79	Effect of gonadal status on bone mineral density and radiological spinal deformities in adult patients with growth hormone deficiency. <i>Pituitary</i> , 2008, 11, 55-61.	1.6	40
80	Prognostic Significance of the Ki-67 Labeling Index in Growth Hormone-Secreting Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 2746-2750.	1.8	89
81	Prevalence of Vertebral Fractures in Men with Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 4649-4655.	1.8	144
82	Microalbuminuria in Insulin Sensitivity in Patients with Growth Hormone-Secreting Pituitary Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 710-714.	1.8	23
83	Significant GH deficiency after long-term cure by surgery in adult patients with Cushing's disease. <i>European Journal of Endocrinology</i> , 2007, 156, 233-239.	1.9	33
84	Increased Total Antioxidant Capacity in Seminal Plasma of Varicocele Patients: A Multivariate Analysis. <i>Archives of Andrology</i> , 2007, 53, 37-42.	1.0	16
85	Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. <i>Endocrine-Related Cancer</i> , 2007, 14, 91-102.	1.6	106
86	Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome. <i>Journal of Endocrinological Investigation</i> , 2007, 30, 948-956.	1.8	26
87	Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. <i>Pituitary</i> , 2007, 10, 227-232.	1.6	42
88	Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: Preliminary report. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 516-522.	1.8	21
89	Increased Prevalence of Radiological Spinal Deformities in Adult Patients With GH Deficiency: Influence of GH Replacement Therapy. <i>Journal of Bone and Mineral Research</i> , 2006, 21, 520-528.	3.1	113
90	Increased Prevalence of Radiological Spinal Deformities in Active Acromegaly: A Cross-Sectional Study in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 1837-1844.	3.1	158

#	ARTICLE	IF	CITATIONS
91	Increased estradiol levels in venous occlusive disorder: a possible functional mechanism of venous leakage. <i>International Journal of Impotence Research</i> , 2005, 17, 239-242.	1.0	34
92	Primary Empty Sella. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 5471-5477.	1.8	203
93	Growth Hormone Secretion and Leptin in Morbid Obesity before and after Biliopancreatic Diversion: Relationships with Insulin and Body Composition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 174-180.	1.8	83
94	Occurrence of Pituitary Dysfunction following Traumatic Brain Injury. <i>Journal of Neurotrauma</i> , 2004, 21, 685-696.	1.7	293
95	Seminal Antioxidant Capacity in Pre- and Postoperative Varicocele. <i>Journal of Andrology</i> , 2004, 25, 44-49.	2.0	37
96	Coenzyme Q10: Another biochemical alteration linked to infertility in varicocele patients?. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 402-406.	1.5	23
97	Body composition and energy expenditure: Relationship and changes in obese subjects before and after biliopancreatic diversion. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 552-558.	1.5	40
98	A Retrospective Hormonal and Immunohistochemical Evaluation of 47 Acromegalic Patients: Prognostic Value of Preoperative Plasma Prolactin. <i>Hormone and Metabolic Research</i> , 2002, 34, 137-143.	0.7	8
99	A case of severe hypertension caused by ACTH-independent macronodular adrenal hyperplasia. <i>Journal of Endocrinological Investigation</i> , 2002, 25, 254-258.	1.8	4
100	Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: A retrospective evaluation of 50 patients. <i>Metabolism: Clinical and Experimental</i> , 2002, 51, 616-621.	1.5	26
101	Opioid dysregulation after biliopancreatic diversion: Effect of naloxone on preprandial and postprandial growth hormone (GH)-releasing hormone-induced GH release in surgically induced weight loss. <i>Metabolism: Clinical and Experimental</i> , 2001, 50, 382-386.	1.5	1
102	Role of Food Intake in the Modulation of Hexarelin-Induced Growth Hormone Release in Normal Human Subjects. <i>Hormone and Metabolic Research</i> , 2000, 32, 152-156.	0.7	8
103	Effects of galanin on growth hormone and prolactin secretion in anorexia nervosa. <i>Metabolism: Clinical and Experimental</i> , 2000, 49, 155-159.	1.5	14
104	Plasma Leptin Levels after Biliopancreatic Diversion: Dissociation with Body Mass Index. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 2386-2389.	1.8	28
105	Hypothalamic derangement in traumatized patients: growth hormone (GH) and prolactin response to thyrotrophin-releasing hormone and GH-releasing hormone. <i>Clinical Endocrinology</i> , 1999, 50, 741-747.	1.2	30
106	Evaluation of pre- and postprandial growth hormone (GH)-releasing hormone-induced GH response in subjects with persistent body weight normalisation after biliopancreatic diversion. <i>International Journal of Obesity</i> , 1998, 22, 1011-1018.	1.6	7
107	Influence of chronic naltrexone treatment on growth hormone secretion in normal subjects. <i>European Journal of Endocrinology</i> , 1997, 137, 631-634.	1.9	5
108	Physiological role of the opioid-cholinergic interaction in growth hormone neuroregulation: Effect of sex and food intake. <i>Metabolism: Clinical and Experimental</i> , 1997, 46, 740-744.	1.5	7

#	ARTICLE	IF	CITATIONS
109	Influence of chronic Naltrexone treatment on growth hormone and insulin secretion in obese subjects. <i>International Journal of Obesity</i> , 1997, 21, 1076-1081.	1.6	11
110	Pre- and postprandial pyridostigmine and oxiracetam effects on growth hormone secretion in anorexia nervosa. <i>Psychoneuroendocrinology</i> , 1996, 21, 621-629.	1.3	6
111	Efficacy and safety of the anabolic therapies in severe osteoporosis: experience of a team of endocrinologists and spine surgeons. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
112	Correlation between atypical pituitary adenomas and Ki-67 Li: clinical and prognostic aspects. <i>Endocrine Abstracts</i> , 0, , .	0.0	0
113	Efficacy of lanreotide autogel in men1-related gastrinomas: a case series. <i>Endocrine Abstracts</i> , 0, , .	0.0	0